Near 52-Week Highs: Is This 88% Margin Biotech Still a Bargain? RSS CTA

Investing.com and Yahoo Finance LLC may earn commission or revenue on some items through the links below.

In a market where cyclical tech swings have unsettled growth portfolios, non-cyclical cash flow is commanding an aggressive premium. While speculative clinical biotechs continue to burn cash on binary trial outcomes, biopharma giant Gilead Sciences (NASDAQ:GILD) surged 15.7% in October, pushing toward 52-week highs following a dominant third-quarter earnings beat and raised full-year guidance.

The rally reflects where institutional capital seeks shelter during sector rotations. Rather than chasing unproven pipeline promises, smart money is gravitating toward established industry leaders with commanding market share, multi-year patent runways, and elite operating margins that reliably fund shareholder dividends regardless of broader economic headwinds.

That demand for insulated, high-margin cash flow powered a flawless 15-for-15 October sweep in ProPicks AI’s Healthcare Heroes strategy. With its November rebalance now live, the portfolio pairs Gilead with an elite group of resilient sector performers—including a diversified specialty pharma turnaround up 43.1% in October, a leading biopharmaceutical pioneer up 14.4%, and a precision laboratory instrumentation leader up 13.1%.

A HIV Franchise That Is Still Gaining Share

Gilead’s third-quarter results on October 29 beat Wall Street estimates: non-GAAP EPS of $2.55 against $2.17, and revenue of $8.3 billion against $7.79 billion. Base business sales rose 16% year over year to $8.2 billion, the strongest growth in over a decade, and Gilead raised its 2026 product sales guidance to between $31.0 billion and $31.3 billion. The shares rose 4.03% that day alone.

HIV is still the core of the business, with sales up 18% to $6.2 billion. Biktarvy reached an all-time high 53% share of the U.S. HIV treatment market and has composition-of-matter patent protection through 2036. A larger-than-typical inventory build also helped the quarter, and management expects softer inventory dynamics in the fourth quarter.

HIV prevention sales nearly doubled, and Yeztugo and Descovy together hold 50% of the PrEP market at a $4 billion annual run rate. Beyond HIV, Trodelvy sales rose 42% to $506 million and Livdelzi, a liver disease drug, rose 93%. Cell therapy, the weak spot, fell 18%.

The pipeline holds 49 clinical programs, and two decisions are close: anito-cel, a multiple myeloma cell therapy, has an FDA decision date of December 23, and once-weekly oral PrEP faces an FDA decision in February 2027.

The Margins and Cash Returns Behind the Run

The Gilead Pro Research Report scores the company on InvestingPro’s Financial Health framework, which ranks companies against sector peers on more than 100 indicators: 7.9 out of 10 for profitability, 6.2 for cash flow and 5.1 for growth. Profitability leads, with an 88% product gross margin and a 50% operating margin in the third quarter that place Gilead in the top quartile of its peers. InvestingPro’s ProTips show 11 consecutive years of dividend increases, and Gilead returned about $1.4 billion to shareholders in the quarter, including $370 million of buybacks.

According to consensus analyst projections compiled on InvestingPro, the stock carries a moderate buy rating, with a high price target of $185.

Management still expects HIV revenue and EPS to grow in 2028, even after Medicare cuts what it pays for Biktarvy by about 38% from January 2028, an estimated $1.5 billion revenue headwind.

The full Gilead Pro Research Report goes deeper on the HIV and oncology pipeline milestones, the Biktarvy patent runway and the dividend coverage.

The Steady Cash Generators in Healthcare

Gilead fits the profile that the data-driven strategies favor in healthcare: non-cyclical, high-margin cash flow, with a five-year beta of 0.33 and a long record of dividend growth. Its HIV franchise is still gaining share, and two FDA decisions are due by February.

ProPicks AI holds Gilead in two strategies, Healthcare Heroes and Beat the S&P 500, where it is up 15.7% in October and 31.8% since entry.

Gilead is one holding among many in the sector. The November rebalance is now live, and the strategies have refreshed their holdings, from recovering drugmakers to makers of laboratory equipment, with Gilead staying in both. Full access to all ProPicks AI strategies, including the live November update, costs $9 a month.

The author holds no position in the stocks mentioned. Data and financial metrics as of November 3, 2026.